Mucous membrane pemphigoid-otorhinolaryngological manifestations: a retrospective cohort study.


Journal

European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
ISSN: 1434-4726
Titre abrégé: Eur Arch Otorhinolaryngol
Pays: Germany
ID NLM: 9002937

Informations de publication

Date de publication:
Mar 2020
Historique:
received: 03 09 2019
accepted: 18 01 2020
pubmed: 26 1 2020
medline: 28 4 2021
entrez: 26 1 2020
Statut: ppublish

Résumé

Mucous membrane pemphigoid (MMP) refers to a heterogeneous group of rare, chronic, inflammatory, mucous membrane-dominated, sub-epithelial blistering diseases that manifest with a varying constellation of oral, ocular, cutaneous, genital, nasopharyngeal, esophageal, and laryngeal lesions. MMP can progress to scarring in affected areas, which may lead to devastating complications including ocular involvement leading to blindness as well as laryngeal involvement leading to airway obstruction. A retrospective chart review was conducted for patients that were followed in two tertiary academic centers between 2009 through 2017 for upper aerodigestive tract manifestations of MMP. Patients with significant underlying skin involvement suggestive of bullous pemphigoid as well as MMP with isolated ocular involvement were excluded. Twenty-seven patients were diagnosed with MMP and followed in two tertiary referral medical centers. The most common site of initial presentation was the oral cavity, and all patients had oral cavity involvement at some point. Two-thirds of our patients had complete remission or remission with intermittent relapses disease. Patients with mild to moderate disease showed excellent response to topical steroid treatment. For more severe disease, high-dose prednisone was insufficient, as in most cases relapse occurred at some point of time during tapering down. MMP is a rare autoimmune disorder that may present with a wide spectrum of head and neck manifestations and, potentially, catastrophic sequelae. This work highlights the experience of two tertiary centers with MMP in an attempt to draw attention to this unusual disorder.

Identifiants

pubmed: 31980882
doi: 10.1007/s00405-020-05812-3
pii: 10.1007/s00405-020-05812-3
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

939-945

Références

Chan LS, Ahmed AR, Anhalt GJ, Bernauer W, Cooper KD, Elder MJ et al (2002) The first international consensus on mucous membrane pemphigoid: definition, diagnostic criteria, pathogenic factors, medical treatment, and prognostic indicators. Arch Dermatol 138(3):370–379
doi: 10.1001/archderm.138.3.370
Darling MR, Daley T (2005) Blistering mucocutaneous diseases of the oral mucosa--a review: part 1. Mucous membrane pemphigoid. J Can Dent Assoc 71(11):851–854
pubmed: 16480600
Murrell DF, Marinovic B, Caux F, Prost C, Ahmed R, Wozniak K et al (2015) Definitions and outcome measures for mucous membrane pemphigoid: recommendations of an international panel of experts. J Am Acad Dermatol 72(1):168–174
doi: 10.1016/j.jaad.2014.08.024
Vaillant L, Bernard P, Joly P, Prost C, Labeille B, Bedane C et al (1998) Evaluation of clinical criteria for diagnosis of bullous pemphigoid. French Bullous Study Group. Arch Dermatol 134(9):1075–1080
doi: 10.1001/archderm.134.9.1075
Sacher C, Hunzelmann N (2005) Cicatricial pemphigoid (mucous membrane pemphigoid): current and emerging therapeutic approaches. Am J Clin Dermatol 6(2):93–103
doi: 10.2165/00128071-200506020-00004
Darling MR, Daley T (2006) Blistering mucocutaneous diseases of the oral mucosa–a review: part 2. Pemphigus vulgaris. J Can Dent Assoc 72(1):63–66
pubmed: 16480607
Alexandre M, Brette MD, Pascal F, Tsianakas P, Fraitag S, Doan S et al (2006) A prospective study of upper aerodigestive tract manifestations of mucous membrane pemphigoid. Medicine (Baltimore) 85(4):239–252
doi: 10.1097/01.md.0000231954.08350.52
Arduino PG, Broccoletti R, Carbone M, Conrotto D, Pettigiani E, Giacometti S et al (2017) Describing the gingival involvement in a sample of 182 Italian predominantly oral mucous membrane pemphigoid patients: a retrospective series. Med Oral Patol Oral Cir Bucal 22(2):e149–e152
pubmed: 28160581 pmcid: 5359700
Kourosh AS, Yancey KB (2011) Therapeutic approaches to patients with mucous membrane pemphigoid. Dermatol Clin 29(4):637–641
doi: 10.1016/j.det.2011.06.022
Buonavoglia A, Leone P, Dammacco R, Di Lernia G, Petruzzi M, Bonamonte D et al (2019) Pemphigus and mucous membrane pemphigoid: an update from diagnosis to therapy. Autoimmun Rev 18(4):349–358
doi: 10.1016/j.autrev.2019.02.005
Maley A, Warren M, Haberman I, Swerlick R, Kharod-Dholakia B, Feldman R (2016) Rituximab combined with conventional therapy versus conventional therapy alone for the treatment of mucous membrane pemphigoid (MMP). J Am Acad Dermatol 74(5):835–840
doi: 10.1016/j.jaad.2016.01.020
Egan CA, Lazarova Z, Darling TN, Yee C, Cote T, Yancey KB (2001) Anti-epiligrin cicatricial pemphigoid and relative risk for cancer. Lancet 357(9271):1850–1851
doi: 10.1016/S0140-6736(00)04971-0
Bernard P, Antonicelli F, Bedane C, Joly P, Le Roux-Villet C, Duvert-Lehembre S et al (2013) Prevalence and clinical significance of anti-laminin 332 autoantibodies detected by a novel enzyme-linked immunosorbent assay in mucous membrane pemphigoid. JAMA Dermatol 149(5):533–540
doi: 10.1001/jamadermatol.2013.1434
Egan CA, Lazarova Z, Darling TN, Yee C, Yancey KB (2003) Anti-epiligrin cicatricial pemphigoid: clinical findings, immunopathogenesis, and significant associations. Medicine (Baltimore) 82(3):177–186
Murakami H, Nishioka S, Setterfield J, Bhogal BS, Black MM, Zillikens D et al (1998) Analysis of antigens targeted by circulating IgG and IgA autoantibodies in 50 patients with cicatricial pemphigoid. J Dermatol Sci 17(1):39–44
doi: 10.1016/S0923-1811(97)00067-4
Yeh SW, Usman AQ, Ahmed AR (2004) Profile of autoantibody to basement membrane zone proteins in patients with mucous membrane pemphigoid: long-term follow up and influence of therapy. Clin Immunol 112(3):268–272
doi: 10.1016/j.clim.2004.04.010
Lazarova Z, Salato VK, Lanschuetzer CM, Janson M, Fairley JA, Yancey KB (2008) IgG anti-laminin-332 autoantibodies are present in a subset of patients with mucous membrane, but not bullous, pemphigoid. J Am Acad Dermatol 58(6):951–958
doi: 10.1016/j.jaad.2008.02.035

Auteurs

Ory Madgar (O)

Department of Otolaryngology and Head and Neck Surgery, Sheba Medical Center, 52621, Tel Hashomer, Israel. ory.madgar@sheba.health.gov.il.
Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. ory.madgar@sheba.health.gov.il.

Avital Baniel (A)

Division of Dermatology, Tel Aviv Sourasky Medical Center, Tel Aviv University, Israel, Tel Aviv, Israel.
Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Noam Yarom (N)

Oral Medicine Unit, Department of Oral Maxillofacial Surgery, Sheba Medical Center, Tel Hashomer, Israel.
Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Goldshlager School of Dental Medicine, Tel Aviv University, Tel Aviv, Israel.

Eran Glikson (E)

Department of Otolaryngology and Head and Neck Surgery, Sheba Medical Center, 52621, Tel Hashomer, Israel.
Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Tal Zeeli (T)

Division of Dermatology, Tel Aviv Sourasky Medical Center, Tel Aviv University, Israel, Tel Aviv, Israel.

Eli Sprecher (E)

Division of Dermatology, Tel Aviv Sourasky Medical Center, Tel Aviv University, Israel, Tel Aviv, Israel.
Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Eran E Alon (EE)

Department of Otolaryngology and Head and Neck Surgery, Sheba Medical Center, 52621, Tel Hashomer, Israel.
Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH